Prosecution Insights
Last updated: November 20, 2026
Application No. 19/187,641

HISTOTRIPSY FOR THROMBOLYSIS

Final Rejection §103§112
Filed
Apr 23, 2025
Priority
Sep 22, 2005 — provisional 60/719,703 +11 more
Examiner
NGUYEN, HIEN NGOC
Art Unit
3797
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
The Regents of the University of Michigan
OA Round
2 (Final)
53%
Grant Probability
Moderate
3-4
OA Rounds
2y 4m
Est. Remaining
94%
With Interview

Examiner Intelligence

Grants 53% of resolved cases
53%
Career Allowance Rate
419 granted / 795 resolved
-17.3% vs TC avg
Strong +41% interview lift
Without
With
+41.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
32 currently pending
Career history
852
Total Applications
across all art units

Statute-Specific Performance

§101
7.3%
-32.7% vs TC avg
§103
51.6%
+11.6% vs TC avg
§102
10.1%
-29.9% vs TC avg
§112
24.1%
-15.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 795 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. DETAILED ACTION Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 2 and 5-12 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Limitation “detecting a location of the bubble cloud with the ultrasound transducer array” is not in the specification. As see in applicant’s specification paragraph [0071] and Fig. 1, the imaging probe not the ultrasound transducer array. The therapy transducer array has hole to insert the imaging/monitor probe/transducer. Claim Rejections - 35 USC § 103 1. The following is a quotation of pre-AIA 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made. 2. Claims 2 and 11-12 are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Xu et al. (Controlled Ultrasound Tissue Erosion (provided in the IDS)), in view of Hall (US 2008/0154132) and further in view of Rabiner (US 2003/0236539). 3. Addressing claim 2, Xu discloses: an ultrasound transducer (see Figs. 1-2, therapy transducer); a motorized positioning system coupled to the ultrasound transducer (see page 727; first paragraph, left column and Fig. 1; 3-axis positioning system; this is the same motorized positioning system as disclosed in applicant’s Fig. 1 and paragraph [0022]); a generator operatively coupled to the ultrasound transducer, the generator and ultrasound transducer being configured to generate cavitation in a target tissue of a subject for controlled mechanical fractionation of the target tissue (see abstract, Figs. 1, 12 and page 726, Introduction section; function generator; tissue erosion is tissue fractionation); at least one processor operatively coupled to the generator and being configured to provide histotripsy therapy to the subject by: outputting an ultrasound pulse sequence from the ultrasound transducer array resulting in cavitation forming a bubble cloud (see Fig. 1, page 734, Discussion section, left column, page 726, Introduction section; the system inherently has a processor; the system produces cavitation by therapy transducer for histotripsy therapy); changing a position of the bubble cloud by mechanically moving the motorized positioning system (see page 727; first paragraph, left column and Fig. 1; 3-axis positioning system move the therapy to change a position of the bubble cloud). Xu does not explicitly disclose an array, detecting a location of the bubble cloud with the ultrasound transducer array and changing a position of the bubble cloud by mechanically moving the motorized positioning system such that the bubble cloud is spatially positioned within the target tissue in response to the location of the bubble cloud. Xu discloses transducer; therapy transducer and monitor transducer together (see page 727, first paragraph, left column and Fig. 1; Xu discloses a therapy transducer with inner diameter hole for a monitoring transducer just like the device disclose by applicant in Fig. 1 and [0071]); however, he does not clearly and explicitly disclose the transducer is an array and monitor is detecting a location of the bubble cloud. Hall explicitly discloses a transducer array and detecting a location of the bubble cloud by imaging/monitoring transducer (see claims 3, 9, 11, [0021], [0027-0028] and Fig. 1; image to see interaction with bubble also detect/image bubble, bright spot is the bubble produce hyperecho scattering; HIFU/therapy transducer is a phased array system; Xu in view of Hall explicitly discloses detecting a location of the bubble cloud with the ultrasound transducer array (examiner interpret this limitation as see in applicant’s Fig. 1 and paragraph [0071]; basically a therapy transducer with a hole for monitoring transducer). Rabiner discloses changing a position of the bubble cloud by actuating the transducer array such that the bubble cloud is spatially positioned within the target tissue in response to the location of the bubble cloud (see Fig. 8, [0009], [0018], [0020], [0023], [0030], [0034], [0067] and [0075]; ultrasound probe 15 aligned with the thrombus 16 in the blood vessel to generate microbubble cloud position at the thrombus to remove the thrombus; Xu discloses changing a position of the bubble cloud by mechanically moving the motorized positioning system and Rabiner discloses align ultrasound probe/transducer with target such that the bubble cloud is spatially positioned within the target tissue in response to the location of the bubble cloud therefore Xu in view of Hall and Rabiner discloses changing a position of the bubble cloud by mechanically moving the motorized positioning system or electronically moving the bubble cloud such that the bubble cloud is spatially positioned within the target tissue in response to the location of the bubble cloud). It would have been obvious to one of ordinary skill in the art at the time of the invention to modify Xu to use an array, detecting a location of the bubble cloud and changing a position of the bubble cloud by actuating transducer such that the bubble cloud is spatially positioned within the target tissue in response to the location of the bubble cloud as taught by Hall and Rabiner because this would improve the efficiency of the treatment (see Hall’s paragraph [0004]; improve cost and successful outcome; Rabiner’s paragraph [0030]; effectively remove tissue, effective, reliable and cost effective). 4. Addressing claims 11-12, Xu discloses: addressing claim 11, comprising an amplifier operatively coupled to the generator and the ultrasound transducer array (see Fig. 1, amplifier connect to function generator and transducer). addressing claim 12, wherein the ultrasound transducer array further comprises a central hole configured to receive an ultrasound imager (see page 727, left column, first paragraph; “a 3.7-cm inner diameter hole for a monitoring/imaging transducer). There is no art rejection for claims 5-10. Response to Arguments Applicant's arguments filed 09/28/26 have been fully considered but they are not persuasive. Applicant argues Hall does not use the same transducer array as the one that generated the bubble cloud as required by claim 2. Applicant’s argument is not persuasive because the specification does not disclose the same transducer array is use for both detecting bubble cloud and therapy generated bubble cloud. Further, Xu discloses the same device therapy transducer with a hole for inserting the imaging/monitor probe/transducer for monitoring target tissue treatment as applicant’s specification; however, he does not explicitly disclose imaging/monitoring target is imaging/detecting bubble cloud. Hall explicitly discloses imaging/monitoring target is detecting/imaging/monitor bubble cloud. Xu in view of Hall discloses the same device to perform the claim function. Applicant argues Rabiner does not disclose detecting a location of a bubble cloud in any form. Applicant argues Rabiner does not disclose changing a position of the bubble cloud by mechanically moving the motorized positioning system. Applicant’s argument is not persuasive because examiner does not rely on Rabiner to disclose this limitation. Applicant’s argument is not persuasive because examiner does not rely on Rabiner to disclose this limitation. Applicant argues since Rabiner does not detect a location, it cannot actuate a transducer array in response to the location, as claimed. Applicant’s argument is not persuasive because the limitation is being rejected as a combination of references. In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See In re Keller, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); In re Merck & Co., 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). Further, one does not need to detect bubble cloud location in order to actuate a transducer array in response to the location of the bubble cloud. As see in Xu’s Fig. 1, one can align the therapy transducer with the target tissue and assume the transducer produce bubble cloud at the target tissue. If the transducer is not aligned with target tissue then one assume that bubble cloud is not at the target tissue therefore actuate the transducer to align with the target tissue to have the bubble cloud generated within the target tissue. This is actuate a transducer array in response to the location of the bubble cloud. The location is assume and not detected. The combination of references would allow one to detect the bubble allow and changing a position of the bubble cloud by mechanically moving the motorized positioning system such that the bubble cloud is spatially positioned within the target tissue in response to the detected location of the bubble cloud. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to HIEN NGOC NGUYEN whose telephone number is (571)270-7031. The examiner can normally be reached Monday-Thursday 8:30am-6:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anne Kozak can be reached at 571-270-0552. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /HIEN N NGUYEN/ Primary Examiner Art Unit 3797
Read full office action

Prosecution Timeline

Apr 23, 2025
Application Filed
Mar 27, 2026
Non-Final Rejection mailed — §103, §112
Sep 28, 2026
Response Filed
Oct 08, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12789016
HISTOTRIPSY EXCITATION SEQUENCES OPTIMIZED FOR BUBBLE CLOUD FORMATION USING SHOCK SCATTERING
7y 6m to grant Granted Nov 10, 2026
Patent 12773227
SURGICAL SYSTEM AND METHODS
1y 11m to grant Granted Oct 27, 2026
Patent 12765950
ELECTROMAGNETIC DISTORTION DETECTION
4y 2m to grant Granted Oct 20, 2026
Patent 12746413
HISTOTRIPSY EXCITATION SEQUENCES OPTIMIZED FOR BUBBLE CLOUD FORMATION USING SHOCK SCATTERING
2y 3m to grant Granted Sep 29, 2026
Patent 12749188
BONE STRENGTH SIMULATION CALCULATION METHOD AND DEVICE, AND STORAGE MEDIUM
1y 8m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
53%
Grant Probability
94%
With Interview (+41.2%)
3y 11m (~2y 4m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 795 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month